CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma

Ait-Tahar, Kamel; Liggins, Amanda P.; Collins, Graham P.; Campbell, Andrew; Barnardo, Martin; Cabes, Maite; Lawrie, Charles H.; Moir, D. J.; Hatton, Chris; Banham, Alison H.; Pulford, Karen

doi:10.3324/haematol.2010.028241

Cited by 12 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Critical role of TCD4 cells is approved in controlling tumor growth and protecting mice against class II MHC negative tumors. It was shown in a study that the transformation of the TCD4 cell-specific adapter of tumor induced virus FBL-3 (MuLV) can control tumor growth in an independent pathway of CTL 46 .On the other hand, the TCD4 cells have also lethal activity to assist host defense against tumors 50 . These cells also secrete cytokines to activate the executive cells of innate immune such as macrophages and NK cells 51 .…”

Section: Immune System Stimulation To Treat Cancermentioning

confidence: 99%

“…The potential of TCD4 generated colonies was subsequently evaluated in identifying the normal processed forms of protein by the tumor cells, therefore, the tumor cells used in this study were manipulated to express class II MHC on the surface. The results showed the ability of TCD4 colonies in reidentifying the antigenic peptides that were naturally processed by tumor cells and presented with class II MHC 46,50,[52][53][78][79][80] .…”

Section: The Role Of Epitopes In Vaccine Designmentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)

Shabgah¹,

Navashenaq²,

Mahboobi³

et al. 2014

Biosci., Biotechnol. Res. Asia

View full text Add to dashboard Cite

Cancer is one of the main causes of mortality in worldwide. When the normal cell division and growth is distorted or on the other hand, the normal cell cycle control processes, which normally occur, are destroyed, the cells will be cancerous. In the event that these cells migrate to other places are known as malignant cancer. Scientists use different methods to treat cancer, such as surgery, chemotherapy, laser therapy. These methods may also cause damage to healthy cells. For this reason, a method is optimal for this purpose as it can involve the least side effects. Immunotherapy is a method in which abnormal cells are Identified and destroyed. Since the immune system is used as the major part in immunotherapy, it is an appropriate method for the purpose. The cancer cells can be detected by immune system and appropriate responses can be taken to them since they induce modifications on the surface, or display their specific antigens. Accordingly, the vaccines can be constructed by which the body will be resistance against cancer. Antigens, especially cancer-specific epitopes are important in vaccine developing. Nowadays scientists have developed several vaccines on this basis, including vaccines against prostate and breast cancers. In this study, we studied various methods of cancer treatment, and then studied the immunotherapy as optimal method in cancer treatment. Ultimately various methods of tumor escape from the immune system will be discussed.

show abstract

Section: Immune System Stimulation To Treat Cancermentioning

confidence: 99%

Section: The Role Of Epitopes In Vaccine Designmentioning

confidence: 99%

Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)

Shabgah¹,

Navashenaq²,

Mahboobi³

et al. 2014

Biosci., Biotechnol. Res. Asia

View full text Add to dashboard Cite

show abstract

“…Peptide sequence Immunogenicity of ways such as stimulating production of antibodies. CD4 responses against PASD1 epitopes were investigated by Ait-Tahar et al [65] in patients with DLBCL. They showed that immunogenic PASD1 epitopes predicted to bind several class II DR beta 1 alleles were able to induce CD4 + T helper responses to PASD1-positive cells from patients with DLBCL.…”

Section: Name Of Epitope Mhc Bindingmentioning

confidence: 99%

“…Further epitopes could be identified through the immunoscreening short overlapping peptide libraries [76,77] although some of the already predicted PASD1 epitopes [63][64][65] remain to be more thoroughly studied in vivo.…”

Section: Development Of Immunotherapy Strategies Targeting Pasd1mentioning

confidence: 99%

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies

Khan¹,

Denniss²

2013

J Genet Syndr Gene Ther

View full text Add to dashboard Cite

In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in outcomes for patients might be achieved. Most patients with haematological malignancies can be treated with conventional therapies such as radio-and chemotherapy and will attain first remission. However the removal of residual diseased cells is essential to prevent relapse and its associated high mortality. PASD1 is one of the most tissue restricted cancer-testis (CT) antigens with expression limited to primary spermatagonia in healthy tissue. However, characterisation of PASD1 expression in cancers has been predominantly focussed on haematological malignancies where the inappropriate expression of PASD1 was first identified. PASD1 has one of the highest frequencies of expression of all CT antigens in acute myeloid leukaemia, with some suggestion of its role as a biomarker in diffuse large B-cell lymphoma. Here we describe the characterisation of the function and expression patterns of PASD1 in cell lines and primary tissues. Development of DNA vaccines targeting PASD1 epitopes demonstrate effective ex vivo T-cell responses in terms of IFNγ secretion and tumour cell killing. Of particular note these vaccines have led to the destruction of cells which process and present endogenous PASD1 indicating that effectively primed CTLs could kill PASD1-positive tumour cells.

show abstract

“…However, this approach has not been effective in clinical trials, probably due to lack of other effector T cells, such as T helper (Th) and memory cells (2) (2). Also, Th cells have a lethal function that helps the host defense system overcome tumor progression (5). Also, these cells prompt executive innate immune cells such as macrophages and NK cells through cytokine secretion (6).…”

Section: Introductionmentioning

confidence: 99%

Effects of Viral Peptide Presentation on CD4+ T Cell Responses to MHC Class II-Restricted Tumor Peptides

et al. 2017

View full text Add to dashboard Cite

Background: Designing a vaccine against a defined tumor is a promising but complicated process that can be used as tumor immunotherapy. The presence of human telomerase reverse transcriptase (hTERT) has been proved in about 85% of tumors; therefore, this enzyme is a promising vaccine target. Most studies in tumor immunotherapy have focused on induction and reinforcement of CD8 + T cell responses against tumor antigens, but some evidence indicates that CD4 + T cell responses are important for induction

show abstract

CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma

Cited by 12 publications

References 37 publications

Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)

Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies

Effects of Viral Peptide Presentation on CD4+ T Cell Responses to MHC Class II-Restricted Tumor Peptides

Contact Info

Product

Resources

About